Below analyst target — what the screen found 2026-11-04
Manufacturing dominates this result, accounting for 32 of the 40 companies that passed the screen on November 3, 2026. Rather than a broad market spread, the list is heavily concentrated in this single sector.
Key figures
Data as of Nov 4, 2026- TVRD (Tvardi Therapeutics, Inc. Common Stock) market cap
- $10.94M
- AARD (Aardvark Therapeutics, Inc. Common Stock) market cap
- $27.36M
- ALGS (Aligos Therapeutics, Inc. Common Stock) market cap
- $29.85M
- EYPT (EyePoint, Inc. Common Stock) market cap
- $33.43M
- IBIO (iBio, Inc. Common Stock) market cap
- $52.85M
- TENX (Tenax Therapeutics, Inc.) market cap
- $68.30M
Manufacturing dominates this result, accounting for 32 of the 40 companies¹˒² that passed the screen on November 3, 2026. Rather than a broad market spread, the list is heavily concentrated in this single sector².
Among the names identified are several small-cap firms including Tvardi Therapeutics ($10.94M³), Aardvark Therapeutics ($27.36M⁴), Aligos Therapeutics ($29.85M⁵), EyePoint ($33.43M⁶), iBio ($52.85M⁷), and Tenax Therapeutics ($68.30M⁸). All these companies operate within the Manufacturing sector.
Every company on this list shares a specific characteristic: they are trading well under a well-covered consensus analyst target. This gap indicates a divergence between current market prices and analyst estimates. Because price targets are rarely revised quickly, a wide gap often reflects a decline in share price rather than a sudden surge in analyst optimism.
Passing this test is not a verdict on a stock's value or an indication that it is worth owning. The screen is a filter that captures a snapshot of data on a specific date; it does not establish whether a stock is a good investment or predict future price movement. No link has been established between these conventional thresholds and forward returns.